Based on our results, we recommend the use of serum instead of fetuin-A alone as a source of protein, lower CPP concentrations determined by particle number, and to consider CPP1 in the experimental set-up to better mimic the in vivo environment of CKD patients. This evidence concerns the gene AHSG and chronic kidney disease.